( CNSX:PBT.U, OTC-BB:PTGEF, OTC-PINK:PTGEF )

News from Biohaven Pharmaceutical Holding Company Ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 15, 2017, 03:00 ET Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase 2 Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage...


Sep 11, 2017, 03:00 ET Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage...


Aug 14, 2017, 06:44 ET Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage...


Aug 07, 2017, 03:00 ET Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has commenced dosing of all 141 randomized patients with...


Aug 04, 2017, 03:00 ET Biohaven Appoints Julia P. Gregory to Board of Directors

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the appointment of Julia P. Gregory, M.B.A., to its Board of Directors....


Jul 31, 2017, 03:00 ET Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has commenced enrollment in the second of its two registrational...


Jul 24, 2017, 03:00 ET Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that it has commenced enrollment in the first of its two registrational...


Jul 13, 2017, 03:00 ET Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs

Biohaven Pharmaceutical Holding Company Ltd. (Biohaven, NYSE: BHVN) announced today that the company has received a Notice of Allowance from the...


Jul 06, 2017, 03:00 ET Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today that BHV-5000, an investigational compound in the company's glutamate...


Jun 23, 2017, 17:00 ET Biohaven Added to Russell Microcap® Index

(NYSE: BHVN) Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) today announced that it has been added to the Russell Microcap® Index as part...


Jun 22, 2017, 03:00 ET Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives

(NYSE: BHVN) - Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) and it's wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today...


Jun 16, 2017, 06:00 ET Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results

(NYSE: BHVN) – Biohaven Pharmaceutical Holding Company Ltd. (Biohaven), a clinical-stage biopharmaceutical company with a portfolio of innovative,...


May 30, 2017, 03:00 ET Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole

(NYSE: BHVN) -- Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) announced today that the company has completed enrollment in its...


May 15, 2017, 03:00 ET Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA

(NYSE: BHVN) -- Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) announced today that the U.S. Food and Drug Administration (FDA) has...


May 11, 2017, 22:40 ET Biohaven Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the closing of its previously announced initial public offering of...


May 04, 2017, 08:48 ET Biohaven Announces Pricing of Initial Public Offering of Common Shares

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the pricing of its initial public offering of 9,900,000 of its common...


May 04, 2017, 08:47 ET Biohaven Announces Pricing of Initial Public Offering of Common Shares

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the pricing of its initial public offering of 9,900,000 of its...


Apr 07, 2017, 17:19 ET Biohaven Files Registration Statement for Proposed Initial Public Offering of Common Shares

Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven") announced today that it has filed a registration statement on Form S-1 with the U.S....


Mar 07, 2017, 03:00 ET Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board

Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), a privately-held, clinical stage biopharmaceutical company with a portfolio of...


Dec 22, 2016, 03:00 ET Biohaven Enrolls First Patient in Pivotal Trial of BHV-4157 in Patients With Hereditary Spinocerebellar Ataxia

Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today that it has enrolled the first patient in its...


Dec 08, 2016, 03:00 ET Biohaven Announces Orphan Drug Designation Request Granted For BHV-0223 In The Treatment Of Amyotrophic Lateral Sclerosis ("ALS")

Biohaven Pharmaceutical Holding Company Ltd. (the "Company" or "Biohaven") announced today that the U.S. Food and Drug Administration ("FDA") has...


Nov 01, 2016, 03:00 ET Biohaven Secures $80 Million in Oversubscribed Private Financing to Advance Phase 3 Clinical Trials

Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), a privately-held biopharmaceutical company with particular expertise in late stage...


Oct 03, 2016, 03:00 ET Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment

 Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") today announced it has acquired the rights from Rutgers, The State...